Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

DRTS vs CRMD: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CRMD Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 6–4 Matrix Metrics)

CRMD Overall Winner 6-Pillar Tally: DRTS 2 – 4 CRMD Matrix Metrics: DRTS 4 – 6 CRMD

As of Nov 17, 2026, CorMedix Inc. (CRMD) is the stronger overall head-to-head candidate over Alpha Tau Medical Ltd. (DRTS) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). DRTS carries a Unified Composite Score of 43.3/100 (HOLD) at $12.09 (N/M Forward P/E, 0.0% operating margin), whereas CRMD carries 55.5/100 (HOLD) at $4.67 (29.5x Forward P/E, 41.0% operating margin).

  • Growth vs. Quality Trade-Off: CRMD earns the overall head-to-head edge with a stronger Unified Composite Score (55.5/100 HOLD vs. DRTS 43.3/100 HOLD) and 1.22β · 103% Vol risk profile, whereas DRTS leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: DRTS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.6); meanwhile CRMD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About DRTS vs CRMD
DRTS NASDAQ
Alpha Tau Medical Ltd. Ordinary Shares
Surgical & Medical Instruments & Apparatus
$12.09
+1.0% 1D
Market Cap $1.2B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.71β · 62% Vol
Unified Composite Score
43.3 / 100 HOLD
Tech 35.0 Fund 54.0 Flow 71.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.3%), weak momentum, RSI 39
RSI-14: 38.6 · SMA20: $13.28 · SMA50: $13.95
CRMD NASDAQ Head-to-Head Winner
CorMedix Inc.
Pharmaceutical Preparations
$4.67
-3.11% 1D
Market Cap $370.6M
TTM Revenue $1.01B
Forward P/E 29.5x
Beta / 30D Vol 1.22β · 103% Vol
Unified Composite Score
55.5 / 100 HOLD
Tech 60.0 Fund 62.0 Flow 70.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -10.1%), weak momentum, RSI 27
RSI-14: 26.8 · SMA20: $6.18 · SMA50: $7.04

6-Pillar Scorecard Institutional Category Breakdown (DRTS 2 – 4 CRMD)

Columns: Metric · DRTS · CRMD
1. Valuation Multiples CRMD
Forward P/E N/M 29.5x
Trailing P/E N/M 2.4x
PEG Ratio N/M 3.32x
EV / Revenue N/M N/M
2. Growth & Scale DRTS
Revenue Growth (YoY) +0.0% -47.7%
Earnings Growth (YoY) +0.0% +6.7%
TTM Revenue (USD) N/A $1.01B
Market Cap $1.2B $370.6M
3. Profitability & Quality CRMD
Gross Margin N/A 87.4%
Operating Margin 0.0% 41.0%
Net Profit Margin 0.0% 15.5%
Return on Equity (ROE) -141.7% 15.3%
4. Balance Sheet & Cash Flow CRMD
Cash Generation (TTM) N/A $755M
Cash Flow Margin N/A 74.6%
Net Cash / Leverage $7.8M Net Cash $514M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning DRTS
Options Structure Phase CONSOLIDATION BREAKDOWN
Current IV / %ile 99.0% (18th %ile) 127.2% (90th %ile)
Put/Call OI Skew 1.47x (Put-Skewed) 2.32x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat CRMD
OpEx & R&D Intensity N/A 46.4% of Rev ($469M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: DRTS (4) vs CRMD (6)
Institutional Metric DRTS CRMD Criterion Row Edge
Market Capitalization
Scale
$1.2B $370.6M Larger Scale DRTS
Trailing P/E Ratio
Valuation
N/M 2.4x Lower Multiple CRMD
Forward P/E Ratio
Valuation
N/M 29.5x Lower Multiple CRMD
Revenue Growth (YoY)
Growth
+0.0% -47.7% Higher Growth DRTS
Operating Margin (TTM)
Profitability
0.0% 41.0% Higher Margin CRMD
Net Profit Margin
Profitability
0.0% 15.5% Higher Margin CRMD
Return on Equity (ROE)
Capital Efficiency
-141.7% 15.3% Higher ROE CRMD
52-Week Range Position
Momentum
70% ($3–$16) 0% ($5–$13) Stronger Trend DRTS
Beta / 30D Volatility
Risk Regime
1.71β · 62% Vol 1.22β · 103% Vol Lower Realized Risk DRTS
Unified Institutional Score
Composite Signal
43.3 / 100 (HOLD) 55.5 / 100 (HOLD) Higher Composite CRMD
Trailing 12M Revenue (USD)
Operating Scale
N/A $1.01B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 87.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 3.32x PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($7.8M Net Cash) $755M ($514M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon DRTS +32.52 pp
DRTS: -4.2% · CRMD: -36.72%
3M Horizon DRTS +28.74 pp
DRTS: -16.45% · CRMD: -45.19%
6M Horizon DRTS +53.48 pp
DRTS: +13.2% · CRMD: -40.28%
1Y Horizon DRTS +283.98 pp
DRTS: +225.53% · CRMD: -58.45%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on DRTS vs CRMD. Trailing 12-month operating profitability (DRTS 0.0% vs CRMD 41.0%) and valuation multiples (DRTS N/M vs CRMD 29.5x Forward P/E) are benchmarked directly in Pillar 4 below.

DRTS ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-141.7% · N/M
CRMD ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.01B
Gross Margin87.4%
Op. Margin41.0%
ROE / Fwd P/E15.3% · 29.5x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
DRTS CONSOLIDATION
95d in phase · OBV NEUTRAL
Current IV 99.0%
IV Percentile 18th %ile
Put/Call OI Skew 1.47x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact DRTS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CRMD BREAKDOWN
110d in phase · OBV DISTRIBUTION
Current IV 127.2%
IV Percentile 90th %ile
Put/Call OI Skew 2.32x (Put-Skewed)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact CRMD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
DRTS Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.2B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CRMD Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $370.6M market capitalization and 41.0% operating margin.
OpEx & R&D Reinvestment 46.4% of Rev ($469M)
90D Engineering Disclosures 0 Published

Investor FAQ DRTS vs CRMD Key Questions & Quantitative Answers

As of Nov 17, 2026, CorMedix Inc. (CRMD) is the stronger overall head-to-head candidate over Alpha Tau Medical Ltd. (DRTS) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). DRTS carries a Unified Composite Score of 43.3/100 (HOLD) at $12.09 (N/M Forward P/E, 0.0% operating margin), whereas CRMD carries 55.5/100 (HOLD) at $4.67 (29.5x Forward P/E, 41.0% operating margin). Growth vs. Quality Trade-Off: CRMD earns the overall head-to-head edge with a stronger Unified Composite Score (55.5/100 HOLD vs. DRTS 43.3/100 HOLD) and 1.22β · 103% Vol risk profile, whereas DRTS leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: DRTS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.6); meanwhile CRMD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

DRTS leads the Growth & Scale pillar: DRTS posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with CRMD at -47.7% YoY revenue growth and +6.7% YoY earnings growth on $1.01B TTM revenue (87.4% gross margin, 41.0% operating margin). On trailing 12-month operating scale, DRTS generates N/A in USD-normalized revenue versus $1.01B for CRMD. In operating R&D and SG&A reinvestment, DRTS deploys N/A (0 90-day corporate R&D disclosures) versus 46.4% of Rev ($469M) (0 disclosures) for CRMD.

CRMD screens cheaper on headline valuation multiples. DRTS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas CRMD trades at 29.5x Forward P/E, 2.4x Trailing P/E, 3.32x PEG, and N/M EV/Revenue (74.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DRTS (-141.7% ROE) versus CRMD (15.3% ROE) capital efficiency.

In options market volatility and institutional positioning, DRTS carries 99.0% implied volatility (18th %ile, Compressed (<25th %ile)), a 1.47x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.71β · 62% Vol realized risk). By comparison, CRMD carries 127.2% implied volatility (90th %ile, Extreme (>80th %ile)), a 2.32x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.22β · 103% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.